Literature DB >> 22387280

A perivascular system releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term study.

Ivo Skalský1, Ondrej Szárszoi, Elena Filová, Martin Pařízek, Andriy Lytvynets, Jana Malušková, Alena Lodererová, Eduard Brynda, Věra Lisá, Zuzana Burdíková, Martin Capek, Jan Pirk, Lucie Bačáková.   

Abstract

The main complication of aortocoronary reconstruction with vein grafts is restenosis in the course of time. The aim was to assess the effect of a periadventitial polyester mesh releasing sirolimus on intimal hyperplasia of autologous grafts. We implanted v. jugularis ext. into a. carotis communis in rabbits. The vein graft was either intact, or was wrapped with a pure polyester mesh, or with a sirolimus-releasing mesh. Three and six weeks after surgery, the veins were subjected to standard histological staining and the thicknesses of the tunica intima, the media and the intima-media complex were measured. Wrapping the vein with a mesh releasing sirolimus or with a pure mesh decreased the thickness of the intima in comparison with a vein graft by 73 ± 11% or 73 ± 8% after 3 weeks, and by 73 ± 9% or 59 ± 12% after 6 weeks, respectively. Sirolimus-releasing meshes reduced the thickness of the media by 65 ± 9% and 20 ± 12% after 3 and 6 weeks. The thickness of the intima-media complex in grafts with sirolimus-releasing meshes decreased by 60 ± 6% and 30 ± 13% in comparison with pure PES meshes, after 3 and 6 weeks, respectively. A periadventitial polyester mesh releasing sirolimus has the potential to become an effective device in preventing vein graft restenosis.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387280     DOI: 10.1016/j.ijpharm.2012.02.023

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Unimolecular Micelle-Based Hybrid System for Perivascular Drug Delivery Produces Long-Term Efficacy for Neointima Attenuation in Rats.

Authors:  Guojun Chen; Xudong Shi; Bowen Wang; Ruosen Xie; Lian-Wang Guo; Shaoqin Gong; K Craig Kent
Journal:  Biomacromolecules       Date:  2017-06-14       Impact factor: 6.988

2.  A rapamycin-releasing perivascular polymeric sheath produces highly effective inhibition of intimal hyperplasia.

Authors:  Xiaohua Yu; Toshio Takayama; Shakti A Goel; Xudong Shi; Yifan Zhou; K Craig Kent; William L Murphy; Lian-Wang Guo
Journal:  J Control Release       Date:  2014-05-20       Impact factor: 9.776

Review 3.  Periadventitial drug delivery for the prevention of intimal hyperplasia following open surgery.

Authors:  Mirnal A Chaudhary; Lian-Wang Guo; Xudong Shi; Guojun Chen; Shaoqin Gong; Bo Liu; K Craig Kent
Journal:  J Control Release       Date:  2016-05-12       Impact factor: 9.776

Review 4.  Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures.

Authors:  Timothy C Boire; Daniel A Balikov; Yunki Lee; Christy M Guth; Joyce Cheung-Flynn; Hak-Joon Sung
Journal:  Macromol Rapid Commun       Date:  2016-09-27       Impact factor: 5.734

5.  Preparation and experimental research into retrievable rapamycin- and heparin-coated vena cava filters: a pilot study.

Authors:  Hui Zhao; Fuxian Zhang; Gangzhu Liang; Lin Ye; Huan Zhang; Luyuan Niu; Long Cheng; Mingyi Zhang
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

6.  Synergy of Rapamycin and Cyanoacrylate in Reducing Intimal Hyperplasia.

Authors:  Marcia Kiyomi Koike
Journal:  Arq Bras Cardiol       Date:  2019-01       Impact factor: 2.000

7.  Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch.

Authors:  J William Tierney; Brian C Evans; Joyce Cheung-Flynn; Bo Wang; Juan M Colazo; Monica E Polcz; Rebecca S Cook; Colleen M Brophy; Craig L Duvall
Journal:  JCI Insight       Date:  2021-10-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.